HWAM
MRTX

Hennion & Walsh Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,831
Closed -$1.4M – 896
2023
Q4 		$1.4M Buy
23,831
+1,295
+6% +$72.8K 0.08% 321
2023
Q3 		$982K Buy
22,536
+1,284
+6% +$45.8K 0.06% 362
2023
Q2 		$768K Sell
21,252
-47
-0.2% -$1.94K 0.05% 423
2023
Q1 		$792K Buy
21,299
+1,536
+8% +$69.1K 0.05% 406
2022
Q4 		$895K Buy
19,763
+10,436
+112% +$675K 0.06% 366
2022
Q3 		$651K Buy
9,327
+2,326
+33% +$172K 0.04% 427
2022
Q2 		$470K Buy
+7,001
New +$445K 0.03% 497
2021
Q4 		– Sell
-8,478
Closed -$1.5M – 792
2021
Q3 		$1.5M Sell
8,478
-2,782
-25% -$448K 0.08% 274
2021
Q2 		$1.82M Sell
11,260
-14,134
-56% -$2.27M 0.1% 256
2021
Q1 		$4.35M Buy
+25,394
New +$5.03M 0.26% 100

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hennion & Walsh Asset Management's MRTX Position: Q1 2024 in Review

Hennion & Walsh Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 23,831 shares — an estimated $1.4M sold.

Hennion & Walsh Asset Management first reported a position in MRTX in Q1 2021 and held it in 10 quarters. The position peaked at $4.35M in Q1 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Hennion & Walsh Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 23,831 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.4M.
  • Hennion & Walsh Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • Hennion & Walsh Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.35M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q1 2024, filed 17 Apr 2024.